Carey, L. A., Rugo, H. S., Marcom, P. K., Irvin, W., Ferraro, M., Burrows, E., … Winer, E. P. (2008). TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. In Journal of Clinical Oncology (Vol. 26, pp. 1009–1009). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2008.26.15_suppl.1009

Carey, L. A., H. S. Rugo, P. K. Marcom, W. Irvin, M. Ferraro, E. Burrows, X. He, C. M. Perou, and E. P. Winer. “TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer.” In Journal of Clinical Oncology, 26:1009–1009. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.1009.

Carey LA, Rugo HS, Marcom PK, Irvin W, Ferraro M, Burrows E, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008. p. 1009–1009.

Carey, L. A., et al. “TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2008, pp. 1009–1009. Crossref, doi:10.1200/jco.2008.26.15_suppl.1009.

Carey LA, Rugo HS, Marcom PK, Irvin W, Ferraro M, Burrows E, He X, Perou CM, Winer EP. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008. p. 1009–1009.